Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Immunotherapy. University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States



Survival: 21.0 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Immunotherapy
   
Drugs:
Country: United States
   
City/State/Province: Pittsburgh, PA
   
Hospital: University of Pittsburgh Cancer Institute
   
Journal: Link
   
Date: 12/2011

Description:
Patients:
This study involved 37 patients with stage IV melanoma. The median patient age was 56 years and 62% were male.

Treatment:

Patients were treated with the biologic therapy agent tremelimumab (a monoclonal antibody that binds to a protein called CTLA-4 and helps the immune system attack tumor cells) and the immunotherapy agent interferon-alpha (IFNa).

Toxicities:
The most severe toxicities were grade 4 diarrhea and changes in enzyme levels. Grade 3 fatigue (15 patients) and depression/anxiety (4) were also reported.

Results:
The median progression-free survival was 6.4 months and the median overall survival was 21 months.

Support:
This study was supported by the pharmaceutical company Pfizer.

Correspondence: Dr. Ahmad A. Tarhini; email: tarhiniaa@upmc.edu

E-mail to a Friend Email Physician More Information